Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001628280-16-021971)

Filing Details

Accession Number:: 0001628280-16-021971
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-12-12 10:10:30
Reporting Period:: 2016-12-09

Filing Date:: 2016-12-12
Accepted Time:: 2016-12-12 10:10:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1600132	Bellerophon Therapeutics Inc.	BLPH	Pharmaceutical Preparations (2834)	473116175

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1631764	Jens Luehring	C/O Linde North America, Inc. 200 Somerset Corporate Blv, Suite 7000 Bridgewater NJ 08807		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-12-09	20,000	$0.56	39,860	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,549,804	Indirect	See footnote

Footnotes

These shares are owned directly by Linde North America, Inc. ("Linde"). Jens Luehring is a director and chief financial officer of Linde. Mr. Luehring disclaims beneficial ownership of all shares held by Linde, except to the extent of his pecuniary interest therein.